Physicians' Academy for Cardiovascular Education

BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?

10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

During a satellite symposium at the ERA-EDTA in Madrid, Spain, organised by PACE-CME, Kamyar Kalantar-Zade, MD shows the data based on which alkaline phosphatase is emerging as a prognostic biomarker of CV events. BET inhibition with apabetalone lowers ALP, and may thus be a promising therapeutic strategy.

Video navigation menu

  • Unmet needs in the management of diabetes and CKD may be met by novel epigenetic therapies that alter transcription of several genes simultaneously.  0:30
  • BET inhibition with apabetalone reduces calcification in in vitro models, likely by downregulation of alkaline phosphatase (ALP) expression 3:31
  • ALP has been linked to mortality, CV disease and diabetes, especially in CKD patients 6:48
  • SInce ALP emerges as an important prognostic biomarker of CV events, can it be lowered in vivo, aiming to reduce events? 11:54
  • Hypothetical model based on in vitro and in vivo data of how BET inhibition may lower ALP expression with potential CV benefit 17:16

Educational information


Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA

CME Accreditation

This lecture was part of a CME accredited symposium: Managing CKD, Diabetes & CVD: Is epigenetics a new way forward? held at ERA-EDTA in Madrid, Spain.


The symposium was supported by an unrestricted educational grant from Resverlogix Corp

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: